News
Legal battle over semaglutide between Novo Nordisk and Indian drugmakers will set precedent for future opportunities and ...
22h
Barchart on MSNEli Lilly vs. Novo Nordisk: Which Stock Is the Winner of the Weight-Loss Drug Boom?The global weight-loss drug market is experiencing exceptional growth, projected to expand from around $144.6 billion in 2023 ...
8h
Stocktwits on MSNHims & Hers Faces Retail Skepticism After Layoffs, FDA Ban on Compounded WegovyRetail investor sentiment around Hims & Hers Health remained negative over the weekend after the telehealth firm confirmed it ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results